Metabolic health is the foundation of longevity. Across cardiovascular disease, cognitive decline, cancer risk, and even fertility, metabolic dysfunction, particularly insulin resistance and visceral adiposity, is now recognized as a root driver rather than a downstream outcome. A comprehensive review published in Academia Medicine reinforces this understanding with concerning evidence that insulin resistance and elevated insulin levels significantly increase the risk of death from cardiovascular disease, cancer, and other causes. This metabolic condition, which now affects more than half the population in developed countries, represents an under-recognized public health crisis that demands immediate attention.
Understanding Insulin Resistance
Insulin resistance occurs when the body’s cells become less responsive to insulin, the hormone that regulates blood sugar. When this happens, the pancreas compensates by producing more insulin, resulting in chronically elevated blood insulin levels, a condition known as hyperinsulinemia. While many people associate insulin problems primarily with diabetes, this new research demonstrates that the implications extend far beyond blood sugar control.
The condition has become increasingly prevalent due to modern lifestyle factors. Sedentary behavior, excessive caloric intake, chronic stress, and the resulting obesity epidemic have created a perfect storm for insulin resistance development. Remarkably, the research indicates that insulin resistance now exceeds 50% prevalence in developed nations, with hyperinsulinemia affecting approximately 45% of adults in the United States, including 30% of normal-weight individuals.
The Mortality Connection
The review, led by Dr. Serafino Fazio and colleagues from Federico II University Hospital in Naples, Italy, analyzed multiple large-scale studies involving hundreds of thousands of participants. The findings paint a sobering picture of insulin resistance’s impact on longevity.
One particularly striking study followed over 22,000 postmenopausal women for nearly 19 years. Women with the highest levels of insulin resistance showed significantly increased rates of both cancer deaths and deaths from all causes. Another analysis of more than 5,500 non-diabetic adults found that those with insulin resistance had substantially higher mortality rates even after accounting for factors such as age, body weight, blood pressure, cholesterol levels, and lifestyle habits.
The research reveals that insulin resistance increases the risk of death through multiple pathways. Beyond its well-established role in type 2 diabetes development, insulin resistance contributes to cardiovascular disease, accelerates cellular aging, promotes cancer development, and may even contribute to neurodegenerative diseases. Each of these conditions independently increases the risk of mortality, creating a compounding effect that significantly shortens life expectancy.
Beyond Diabetes: A Broader Health Threat
Perhaps most concerning is the finding that insulin resistance increases mortality risk even in people without diabetes. The review highlights studies showing that non-diabetic individuals with insulin resistance face increased risks of cardiovascular death and cancer mortality. This challenges the conventional medical approach that typically only addresses insulin problems after a diabetes diagnosis.
The research also reveals a particularly troubling finding regarding insulin treatment in diabetic patients with existing insulin resistance. When insulin is administered to patients who already have insulin resistance without first addressing the underlying resistance, it may actually increase mortality risk. This suggests that simply treating high blood glucose with additional insulin, without addressing the root cause of insulin resistance, could do more harm than good.
The Need for Action
The authors argue forcefully that insulin resistance should be recognized as an independent risk factor for multiple diseases and mortality, similar to how medical professionals view high blood pressure or elevated cholesterol. They call for routine screening of insulin resistance in the general population, particularly given that the condition often develops silently over many years before causing noticeable symptoms.
Early detection is crucial because insulin resistance is often reversible through lifestyle modifications. Regular physical activity, dietary changes that reduce insulin-stimulating foods, weight management, and stress reduction can all improve insulin sensitivity. For those who cannot achieve normal insulin function through lifestyle changes alone, medications that improve insulin sensitivity are available.
Implications for Public Health
The economic and social implications of widespread insulin resistance are staggering. The condition drives increased hospitalizations, escalating healthcare costs, and premature deaths across all age groups. With the global prevalence of type 2 diabetes expected to continue rising dramatically through 2030, addressing insulin resistance at its roots becomes not just a medical priority but an economic necessity.
The review emphasizes that current approaches to managing cardiovascular disease may be missing a critical component. While medicine has made significant strides in treating cholesterol and blood pressure, cardiovascular disease remains the leading cause of death in Western nations. The authors suggest that unrecognized insulin resistance may contribute to this “residual risk” that persists despite aggressive treatment of traditional risk factors.
The Industrial Context: Profit Over Prevention
The food and medical industries are deeply intertwined in the story of insulin resistance, and both profit from its widespread development. On the food side, the system is built around ultra-processed products that are cheap to manufacture but sold at high margins. These foods are deliberately engineered with the right balance of sugar, fat, and salt to hit what’s called the “bliss point,” making them highly palatable and difficult to resist. Because they are calorie-dense but nutrient-poor, they drive repeated spikes in blood sugar and insulin, which, over time, contribute to insulin resistance. Marketing campaigns, often aimed at children and families, normalize these products as everyday staples, while whole, unprocessed foods remain less profitable and therefore less aggressively promoted. The result is a population consuming diets that steadily erode metabolic health, while food companies reap the rewards of high-volume sales.
On the medical side, the consequences of insulin resistance (type 2 diabetes, obesity, cardiovascular disease, and fatty liver disease) are not conditions that are cured but rather managed indefinitely. This creates a reliable and lucrative market for pharmaceutical companies, device manufacturers, and healthcare providers. Insulin has experienced dramatic price increases in the United States, far outpacing production costs, while newer drugs such as GLP-1 agonists, including Ozempic and Wegovy, can cost patients up to a thousand dollars per month despite being inexpensive to produce. Beyond medications, the industry profits from the ongoing need for diagnostic tools, glucose monitors, and frequent lab testing. People with diabetes spend more than twice as much on healthcare as those without, ensuring a steady stream of revenue for the system as a whole.
Together, these industries form a feedback loop. The food industry drives the conditions that lead to insulin resistance, while the medical industry steps in to manage the fallout. Both sides profit: one from selling addictive, low-cost foods, the other from providing lifelong treatments and monitoring. Prevention, which would entail encouraging healthier diets and lifestyles, is far less profitable; therefore, incentives remain aligned with managing disease rather than eliminating its root causes. This misalignment leaves individuals bearing the health consequences and financial burdens, while the industries themselves thrive on the persistence of the problem.
Moving Forward
This research presents a compelling case for a paradigm shift in how we approach metabolic health. The evidence makes clear that metabolic health is the foundation of longevity, not merely one factor among many. Across cardiovascular disease, cognitive decline, cancer risk, and fertility, metabolic dysfunction, particularly insulin resistance and visceral adiposity, functions as a root driver rather than a downstream outcome. This understanding demands that we stop treating metabolic problems as consequences of other diseases and recognize them as primary causes requiring early intervention. Rather than waiting for diabetes or cardiovascular disease to develop, healthcare systems should implement proactive screening for insulin resistance, particularly in at-risk populations. Given that the condition can begin in childhood and progress silently for decades, early intervention could prevent countless premature deaths and reduce the burden of chronic disease.
For individuals seeking to address insulin resistance, finding the right healthcare provider is crucial. Not all medical professionals are equally versed in the dietary and lifestyle interventions that can effectively reverse insulin resistance. Patients should seek providers who recognize that insulin resistance is often reversible through targeted nutritional strategies, structured exercise programs, stress-management techniques, and other lifestyle modifications. These practitioners should be knowledgeable about approaches such as reducing refined carbohydrate intake, implementing strategic meal timing, incorporating resistance training, and addressing sleep quality, all of which are evidence-based methods for improving insulin sensitivity. A provider who immediately reaches for medication without first exploring these foundational interventions may be missing critical opportunities for reversal.
The importance of this expertise cannot be overstated. While medications certainly have their place in treatment, the research clearly indicates that lifestyle modifications remain the most powerful tools for addressing insulin resistance at its root cause. Healthcare providers who are well-versed in these approaches can guide patients through sustainable changes that not only improve insulin sensitivity but also enhance overall metabolic health. They can help patients understand which foods trigger excessive insulin responses, how to structure meals for optimal blood sugar control, and which types of physical activity most effectively improve insulin function.
Simple blood tests can assess insulin resistance using measures such as fasting insulin levels or calculated indices, such as HOMA-IR. However, interpreting these results and developing an effective treatment plan requires a provider who understands the nuances of metabolic health. For individuals with insulin resistance, working with a knowledgeable healthcare professional to implement comprehensive lifestyle modifications could be life-saving. When these interventions prove insufficient, such providers can then judiciously incorporate medical treatments while continuing to emphasize the foundational importance of diet and lifestyle.
As our understanding of the far-reaching effects of insulin resistance continues to grow, it becomes increasingly apparent that this metabolic dysfunction is one of the most significant yet addressable threats to public health in the modern era. The time for action, both at the individual and societal levels, is now.
